Clinical sensitivity and specificity of a high-throughput microfluidic nano-immunoassay combined with capillary blood microsampling for the identification of anti-SARS-CoV-2 Spike IgG serostatus
<h4>Objectives</h4> We evaluate the diagnostic performance of dried blood microsampling combined with a high-throughput microfluidic nano-immunoassay (NIA) for the identification of anti-SARS-CoV-2 Spike IgG seropositivity. <h4>Methods</h4> We conducted a serological study am...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2023-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035827/?tool=EBI |
| _version_ | 1797860185281134592 |
|---|---|
| author | Grégoire Michielin Fatemeh Arefi Olha Puhach Mathilde Bellon Pascale Sattonnet-Roche Arnaud G. L’Huillier Isabella Eckerle Benjamin Meyer Sebastian J. Maerkl |
| author_facet | Grégoire Michielin Fatemeh Arefi Olha Puhach Mathilde Bellon Pascale Sattonnet-Roche Arnaud G. L’Huillier Isabella Eckerle Benjamin Meyer Sebastian J. Maerkl |
| author_sort | Grégoire Michielin |
| collection | DOAJ |
| description | <h4>Objectives</h4> We evaluate the diagnostic performance of dried blood microsampling combined with a high-throughput microfluidic nano-immunoassay (NIA) for the identification of anti-SARS-CoV-2 Spike IgG seropositivity. <h4>Methods</h4> We conducted a serological study among 192 individuals with documented prior SARS-CoV-2 infection and 44 SARS-CoV-2 negative individuals. Participants with prior SARS-CoV-2 infection had a long interval of 11 months since their qRT-PCR positive test. Serum was obtained after venipuncture and tested with an automated electrochemiluminescence anti-SARS-CoV-2 S total Ig reference assay, a commercial ELISA anti-S1 IgG assay, and the index test NIA. In addition, 109 participants from the positive cohort and 44 participants from the negative cohort participated in capillary blood collection using three microsampling devices: Mitra, repurposed glucose test strips, and HemaXis. Samples were dried, shipped by regular mail, extracted, and measured with NIA. <h4>Results</h4> Using serum samples, we achieve a clinical sensitivity of 98·33% and specificity of 97·62% on NIA, affirming the high performance of NIA in participants 11 months post infection. Combining microsampling with NIA, we obtain a clinical sensitivity of 95·05% using Mitra, 61·11% using glucose test strips, 83·16% using HemaXis, and 91·49% for HemaXis after automated extraction, without any drop in specificity. <h4>Discussion</h4> High sensitivity and specificity was demonstrated when testing micro-volume capillary dried blood samples using NIA, which is expected to facilitate its use in large-scale studies using home-based sampling or samples collected in the field. |
| first_indexed | 2024-04-09T21:41:43Z |
| format | Article |
| id | doaj.art-dd4365c9b2b944a58d2a308468119529 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-04-09T21:41:43Z |
| publishDate | 2023-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-dd4365c9b2b944a58d2a3084681195292023-03-26T05:32:08ZengPublic Library of Science (PLoS)PLoS ONE1932-62032023-01-01183Clinical sensitivity and specificity of a high-throughput microfluidic nano-immunoassay combined with capillary blood microsampling for the identification of anti-SARS-CoV-2 Spike IgG serostatusGrégoire MichielinFatemeh ArefiOlha PuhachMathilde BellonPascale Sattonnet-RocheArnaud G. L’HuillierIsabella EckerleBenjamin MeyerSebastian J. Maerkl<h4>Objectives</h4> We evaluate the diagnostic performance of dried blood microsampling combined with a high-throughput microfluidic nano-immunoassay (NIA) for the identification of anti-SARS-CoV-2 Spike IgG seropositivity. <h4>Methods</h4> We conducted a serological study among 192 individuals with documented prior SARS-CoV-2 infection and 44 SARS-CoV-2 negative individuals. Participants with prior SARS-CoV-2 infection had a long interval of 11 months since their qRT-PCR positive test. Serum was obtained after venipuncture and tested with an automated electrochemiluminescence anti-SARS-CoV-2 S total Ig reference assay, a commercial ELISA anti-S1 IgG assay, and the index test NIA. In addition, 109 participants from the positive cohort and 44 participants from the negative cohort participated in capillary blood collection using three microsampling devices: Mitra, repurposed glucose test strips, and HemaXis. Samples were dried, shipped by regular mail, extracted, and measured with NIA. <h4>Results</h4> Using serum samples, we achieve a clinical sensitivity of 98·33% and specificity of 97·62% on NIA, affirming the high performance of NIA in participants 11 months post infection. Combining microsampling with NIA, we obtain a clinical sensitivity of 95·05% using Mitra, 61·11% using glucose test strips, 83·16% using HemaXis, and 91·49% for HemaXis after automated extraction, without any drop in specificity. <h4>Discussion</h4> High sensitivity and specificity was demonstrated when testing micro-volume capillary dried blood samples using NIA, which is expected to facilitate its use in large-scale studies using home-based sampling or samples collected in the field.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035827/?tool=EBI |
| spellingShingle | Grégoire Michielin Fatemeh Arefi Olha Puhach Mathilde Bellon Pascale Sattonnet-Roche Arnaud G. L’Huillier Isabella Eckerle Benjamin Meyer Sebastian J. Maerkl Clinical sensitivity and specificity of a high-throughput microfluidic nano-immunoassay combined with capillary blood microsampling for the identification of anti-SARS-CoV-2 Spike IgG serostatus PLoS ONE |
| title | Clinical sensitivity and specificity of a high-throughput microfluidic nano-immunoassay combined with capillary blood microsampling for the identification of anti-SARS-CoV-2 Spike IgG serostatus |
| title_full | Clinical sensitivity and specificity of a high-throughput microfluidic nano-immunoassay combined with capillary blood microsampling for the identification of anti-SARS-CoV-2 Spike IgG serostatus |
| title_fullStr | Clinical sensitivity and specificity of a high-throughput microfluidic nano-immunoassay combined with capillary blood microsampling for the identification of anti-SARS-CoV-2 Spike IgG serostatus |
| title_full_unstemmed | Clinical sensitivity and specificity of a high-throughput microfluidic nano-immunoassay combined with capillary blood microsampling for the identification of anti-SARS-CoV-2 Spike IgG serostatus |
| title_short | Clinical sensitivity and specificity of a high-throughput microfluidic nano-immunoassay combined with capillary blood microsampling for the identification of anti-SARS-CoV-2 Spike IgG serostatus |
| title_sort | clinical sensitivity and specificity of a high throughput microfluidic nano immunoassay combined with capillary blood microsampling for the identification of anti sars cov 2 spike igg serostatus |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035827/?tool=EBI |
| work_keys_str_mv | AT gregoiremichielin clinicalsensitivityandspecificityofahighthroughputmicrofluidicnanoimmunoassaycombinedwithcapillarybloodmicrosamplingfortheidentificationofantisarscov2spikeiggserostatus AT fatemeharefi clinicalsensitivityandspecificityofahighthroughputmicrofluidicnanoimmunoassaycombinedwithcapillarybloodmicrosamplingfortheidentificationofantisarscov2spikeiggserostatus AT olhapuhach clinicalsensitivityandspecificityofahighthroughputmicrofluidicnanoimmunoassaycombinedwithcapillarybloodmicrosamplingfortheidentificationofantisarscov2spikeiggserostatus AT mathildebellon clinicalsensitivityandspecificityofahighthroughputmicrofluidicnanoimmunoassaycombinedwithcapillarybloodmicrosamplingfortheidentificationofantisarscov2spikeiggserostatus AT pascalesattonnetroche clinicalsensitivityandspecificityofahighthroughputmicrofluidicnanoimmunoassaycombinedwithcapillarybloodmicrosamplingfortheidentificationofantisarscov2spikeiggserostatus AT arnaudglhuillier clinicalsensitivityandspecificityofahighthroughputmicrofluidicnanoimmunoassaycombinedwithcapillarybloodmicrosamplingfortheidentificationofantisarscov2spikeiggserostatus AT isabellaeckerle clinicalsensitivityandspecificityofahighthroughputmicrofluidicnanoimmunoassaycombinedwithcapillarybloodmicrosamplingfortheidentificationofantisarscov2spikeiggserostatus AT benjaminmeyer clinicalsensitivityandspecificityofahighthroughputmicrofluidicnanoimmunoassaycombinedwithcapillarybloodmicrosamplingfortheidentificationofantisarscov2spikeiggserostatus AT sebastianjmaerkl clinicalsensitivityandspecificityofahighthroughputmicrofluidicnanoimmunoassaycombinedwithcapillarybloodmicrosamplingfortheidentificationofantisarscov2spikeiggserostatus |